Entelo Acquires ConveyIQ
Today, Entelo announces the acquisition of ConveyIQ, the leading provider of candidate engagement Software-as-a-Service solutions. Read more >>
Today, Entelo announces the acquisition of ConveyIQ, the leading provider of candidate engagement Software-as-a-Service solutions. Read more >>
First Data is offering a new benefit to 10,000 eligible employees to better enable them to pay down student loans. The financial services company is now allowing workers to earn performance rewards points to pay down their debt. The new program is offered in partnership with student loan benefit provider FutureFuel.io.Read more >>
UMassFive College Federal Credit Union announced it is bringing student-loan repayment benefits to its employees via a new partnership between Student Choice and FutureFuel.io. Read more >>
Myomo, Inc., a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, today announced that it has launched a business development program to bring its proprietary MyoPro orthotic product line to a greater number of country markets outside of the United States. Read more >>
Siamab Therapeutics, Inc., a biopharmaceutical company developing novel glycan-targeted cancer therapeutics, has entered into a strategic agreement valued at up to $202 million with an undisclosed, large commercial-stage biopharmaceutical company under which such company will develop and commercialize antibody-based products targeting a tumor-associated carbohydrate antigen (TACA) identified by Siamab’s proprietary TACA discovery platform. Read more >>
PlaceMe is acquiring the majority of Bedly’s Boston properties in a deal recently finalized. As a result, PlaceMe has become Boston’s largest co-living company, with over 150 fully-furnished bedrooms available for co-living. Read more >>
Technology being developed at the University of Arizona could help those who are legally blind or who have impaired eyesight to see.Read more >>
Working out of sites in Korea and the U.S., D&D serves as the parent company for three spinouts from Johns Hopkins School of Medicine. The highest profile of the three subsidiaries is Neuraly, which raised a $36 million series A round last year to take long-acting glucagon-like peptide-1 receptor agonist NLY01 into the clinic.Read more >>
ALK today announced that it has finalised its strategy for entering the US market for epinephrine (adrenaline) auto-injectors (EAIs) and that this will focus on a next-generation EAI in partnership with US-based Windgap Medical. Read more >>
It’s that time of year again when some parents go on the hunt for an elusive pharmaceutical product. Once again, epinephrine injectable pens — or EpiPens — are in short supply, but a local company is making steady strides toward a possible solution. Read more >>